REPROGRAMMING HUMAN ENDOTHELIUM IN HEMATOPOIETIC PRECURSORS OF MULTIPLE LINES OF DIFFERENTIATION USING CERTAIN FACTORS Russian patent published in 2019 - IPC A61K35/44 A61P7/02 A61P35/02 C12N5/73 

FIELD: pharmaceuticals.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for producing hematopoietic precursors of differentiation lines (HMLP) from endothelial cells (EC). A method for producing human HMLP from human EC, involving culturing EC, transduced by one or more vectors triggering the expression of each of the transcription factors: homologue B of osteosarcoma virus oncogene of mouse Finkel-Biskis-Jinkins (FOSB) or functional derivative thereof, having at least 90 % amino acid sequence FOSB identity, growth factor-independent transcriptional repressor 1 (GFI1) or functional derivative thereof, having at least 90 % amino acid sequence identity of GFI1, Runt-related transcription factor 1 (RUNX1) or its functional derivative, having at least 90 % amino acid sequence identity RUNX1, provisional oncogene of integrating a virus forming foci in spleen, (SPI1) or its functional derivative, having at least 90 % amino acid sequence identity SPI1, in a serum-free haemopoietic medium with endothelial feeder cells transformed for expression of either the open reading frame 1 E4 adenovirus (E4ORF1) gene or the Akt gene. A HMLP population for intravenous infusion to a patient with hematopoietic disorder. A composition for intravenous infusion to a patient with hematopoietic disorder. A method of treating hematopoietic disorder.

EFFECT: disclosed method enables to obtain HMLP with a mixture of cell types, wherein each cell type has separate cell markers and / or a separate level of differentiation.

23 cl, 28 dwg, 1 tbl